The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.

Medical professionals are voicing mounting concern over patient safety following the People's Party's proposal to allow the ...

The therapy is a highly advanced form of radiation therapy that uses charged particles in the form of a proton that that gets ...

Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show ...

Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show that cancer drug treatments can be safely and effectively personalized based ...

A recent study by the Laboratory for Neuro-Analysis and Imaging (LANAI) at UMass Chan Medical School highlights how subcortical brain structures degenerate in Alzheimer's disease and frontotemporal ...

Self-administered injectable contraceptives have been available in the United States for more than two decades, yet a new ...

A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how politics will impact innovation long term.